Preventing AIDS deaths: Cryptococcal antigen screening and treatment

The Lancet Infectious Diseases

Volumn 12, Issue 6, 2012, Pages 431-432

  Klausner, Jeffrey D ^a   Govender, Nelesh ^b   Oladoyinbo, Samuel ^c   Roy, Monika ^d   Chiller, Tom ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c Centers for Disease Prevention and Control   (South Africa)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; FUNGUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; COST EFFECTIVENESS ANALYSIS; CRYPTOCOCCOSIS; DEATH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATEX AGGLUTINATION TEST; LETTER; PRIORITY JOURNAL; SCREENING TEST;

ANTIBIOTIC PROPHYLAXIS; ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; FEMALE; FLUCONAZOLE; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE;

EID: 84861415055     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70094-4     Document Type: Letter

References (4)

1. Parkes-Ratanshi R, Wakeham K, Levin J, et al. Primary prophylaxis of cryptococcal disease with fluconazole in HIV-positive Ugandan adults: a double-blind, randomized, placebo-controlled trial. Lancet Infect Dis 2011, 11:933-941.
2. Jarvis JN, Harrison TS, Govender N, et al. Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts-time to implement in South Africa?. S Afr Med J 2011, 101:232-234.
3. Roy M, Chiller TM Preventing deaths from cryptococcal meningitis:from bench to bedside. Expert Rev Anti Infect Ther 2011, 9:715-717.
4. Jarvis JN, Percival A, Bauman S Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis 2011, 53:1019-1023.